Drug Release Classification

1. Immediate Release (IR)

• Drug is released rapidly after administration (within 30-60 minutes).
• No deliberate effort is made to modify rate or timing of release.
• Produces quick but short-lived plasma peaks (high fluctuation between doses).
• Used for: Acute conditions - pain, fever, infection, seizures.
• Examples: Standard tablets, uncoated capsules, syrups.
• Label: IR, no special suffix.

2. Modified Release (MR) - Umbrella Term

A. Extended Release (ER / XR / XL / LA)

• Drug releases slowly over 12-24 hours, reducing dosing to once or twice daily.
• Defined by FDA as allowing at least a 2-fold reduction in dosing frequency compared to IR.
• Plasma levels are more stable with fewer peaks and troughs.
• EMA equivalent: Prolonged-release.
• Mechanisms: Matrix tablets (HPMC), reservoir systems, osmotic pumps (OROS).
• Examples: Metformin XR, Metoprolol XL, Nifedipine LA, Diltiazem CD.

B. Sustained Release (SR)

• Functionally similar to ER - releases drug over a prolonged period.
• Not a distinct FDA regulatory category but widely used commercially.
• Moderate plasma level fluctuation; not as flat a profile as controlled release.
• Examples: Morphine SR, Tramadol SR, Theophylline SR.

C. Controlled Release (CR)

• Drug is released at a predetermined, constant rate to maintain a steady therapeutic plasma level (zero-order or near-zero-order kinetics).
• Minimal plasma fluctuation - closest to a continuous infusion effect.
• Not a specific FDA category - often used interchangeably with ER in labeling.
• EMA: Falls under modified-release.
• Examples: Osmotic pump systems (OROS), reservoir-type transdermal patches.

D. Delayed Release (DR) / Enteric Coated (EC)

• Drug is not released immediately but at a later time or site (typically bypassing the stomach).
• Enteric coating resists gastric acid (pH ~1-2) and dissolves at intestinal pH (~6-7).
• EMA equivalent: Gastro-resistant.
• Purpose: Protect acid-labile drugs (omeprazole, enteric aspirin), reduce gastric irritation, deliver drug to colon.
• Examples: Omeprazole EC, Diclofenac EC, Aspirin EC, Mesalamine DR.

3. Pulsatile Release

• Drug is released in discrete pulses at programmable time intervals.
• Useful for chronopharmacological conditions (asthma at night, morning hypertension).
• Technology: TIME CLOCK system, PORT system, rupturable coatings.

4. Targeted / Site-Specific Release

• Drug is directed to a specific organ, tissue, or cell type.
• Sub-types:
  • Colon-targeted: Mesalamine, budesonide for IBD.
  • Tumor-targeted: Liposomal doxorubicin, antibody-drug conjugates.
  • Brain-targeted: Lipid nanoparticles crossing the blood-brain barrier.

5. Stimulus-Responsive Release

• Drug releases in response to an internal or external trigger.
• Triggers: pH, temperature, enzymes, light, ultrasound, magnetic fields, glucose levels.
• Example: Insulin delivery systems responsive to blood glucose.

Summary Table

Regulatory Nomenclature Comparison

Mechanism-Based Classification of Controlled Release Systems

1. Dissolution-controlled - coating dissolves slowly (reservoir, matrix types)
2. Diffusion-controlled - drug diffuses through a membrane or matrix
3. Osmotic pressure-controlled - water enters tablet via semipermeable membrane, pushing drug out (OROS - osmotic pump)
4. Swelling-controlled - polymer swells on contact with water, releasing drug
5. Chemically controlled - drug linked to polymer; released by hydrolysis/enzymatic cleavage
6. Nanoparticle-based - liposomes, polymeric nanoparticles, solid lipid nanoparticles

• Park's Textbook of Preventive and Social Medicine, p. 547 (dosage form classification)
• Colorcon: Controlled vs Sustained vs Extended Release (regulatory comparison)
• PMC: Controlled Drug Delivery Systems (mechanism-based classification)